back

PRESS RELEASE

United Therapeutics Corporation To Present at Jefferies 2019 Healthcare Conference

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., May 28, 2019 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that James Edgemond, Chief Financial Officer and Treasurer of United Therapeutics, will provide an overview and update on the company's business at the Jefferies 2019 Healthcare Conference in New York City.

The presentation will take place on Tuesday, June 4, 2019, at 1:30 PM Eastern Time, and can be accessed via a live webcast on the United Therapeutics website at http://www.unither.com under the "Investors" tab in the "Events and Presentations" section. An archived, recorded version of the presentation will be available approximately twenty-four hours after the presentation ends and can be accessed at the same location for 90 days. [uthr-g]

View original content:http://www.prnewswire.com/news-releases/united-therapeutics-corporation-to-present-at-jefferies-2019-healthcare-conference-300856744.html

SOURCE United Therapeutics Corporation

Recent Press Releases

09 Nov 2026

United Therapeutics Corporation Announces Participation at Upcoming Investor Conferences

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR) announced today that James Edgemond, Chief Financial Officer and Treasurer, will provide an...

Download pdf

04 Nov 2026

United Therapeutics Announces Buydown of Ralinepag Royalty

The transaction eliminates the double-digit royalty payable to Pfizer on net sales of ralinepag Royalty elimination applies to all formulations of ralinepag, including both oral and inhaled SILVER SPRING, Md...

Download pdf

04 Nov 2026

United Therapeutics Corporation Reports Third Quarter 2026 Financial Results

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended...

Download pdf

28 Oct 2026

United Therapeutics Announces FDA Clearance to Proceed with Clinical Trial for Treprostinil-Iloprost SMI in Pulmonary Arterial Hypertension

If successful, Treprostinil-Iloprost SMI would be the first use-as-needed combination inhaled therapy to be developed for pulmonary arterial hypertension (PAH) This investigational therapy combines two potent...

Download pdf

22 Oct 2026

United Therapeutics Corporation Announces Additional $2 Billion Share Repurchase Authorization

SILVER SPRING, M.D. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the company’s Board of Directors has...

Download pdf

21 Oct 2026

United Therapeutics Corporation to Report Third Quarter 2026 Financial Results Before Market Open on Wednesday, November 4, 2026

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its third quarter 2026 financial results in a press release...

Download pdf

view all